Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety
The coexistence of cardiovascular disease and erectile dysfunction is widespread, possibly owing to underlying endothelial dysfunction in both diseases. Millions of patients with cardiovascular disease are prescribed phosphodiesterase-5 (PDE5) inhibitors for the management of erectile dysfunction. A...
Gespeichert in:
| Veröffentlicht in: | Cardiovascular drugs and therapy 2023-08, Vol.37 (4), p.793-806 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 806 |
|---|---|
| container_issue | 4 |
| container_start_page | 793 |
| container_title | Cardiovascular drugs and therapy |
| container_volume | 37 |
| creator | Roy, Sumon Kloner, Robert A. Salloum, Fadi N. Jovin, Ion S. |
| description | The coexistence of cardiovascular disease and erectile dysfunction is widespread, possibly owing to underlying endothelial dysfunction in both diseases. Millions of patients with cardiovascular disease are prescribed phosphodiesterase-5 (PDE5) inhibitors for the management of erectile dysfunction. Although the role of PDE5 inhibitors in erectile dysfunction therapy is well established, their effects on the cardiovascular system are unclear. Preclinical studies investigating the effect of PDE5 inhibitors on ischemia–reperfusion injury, pressure overload-induced hypertrophy, and chemotoxicity suggested a possible clinical role for each of these medications; however, attempts to translate these findings to the bedside have resulted in mixed outcomes. In this review, we explore the biologic preclinical effects of PDE5 inhibitors in mediating cardioprotection. We then examine clinical trials investigating PDE5 inhibition in patients with heart failure, coronary artery disease, and ventricular arrhythmias and discuss why the studies likely have yet to show positive results and efficacy with PDE5 inhibition despite no safety concerns. |
| doi_str_mv | 10.1007/s10557-021-07275-y |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9010479</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2582807851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c430t-7ba169f0cdeddf9c86832ca3c13cca64e90cdfadde91a6bfa0366ab7d5c87513</originalsourceid><addsrcrecordid>eNp9kUtvFDEQhC0EIkvgD3BAI3HhYmjb47HNAQmtEogUCSRyt3r8yDraHS_2LNL8e5xsCI8DJx_qq2p3FyEvGbxlAOpdZSClosAZBcWVpMsjsmJSCap4zx6TFRgOVHAYTsizWm-gmYzRT8mJ6AfJpWYrcr7G4hO67izG4Oba5dh93eS632SfQp1DwRqo7C6mTRrTnEt9f4smh27pcPLdN4xhXp6TJxG3Nby4f0_J1fnZ1fozvfzy6WL98ZK6XsBM1YhsMBGcD95H4_SgBXcoHBPO4dAH06SI3gfDcBgjghgGHJWXTivJxCn5cIzdH8Zd8C5Mc8Gt3Ze0w7LYjMn-rUxpY6_zD2uAQa9MC3hzH1Dy90Pbz-5SdWG7xSnkQ7XtKFyD0nezXv-D3uRDmdp2luu-b6cFoxvFj5QrudYS4sNnGNjbluyxJdtasnct2aWZXv25xoPlVy0NEEegNmm6DuX37P_E_gTaSZ8p</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2844920098</pqid></control><display><type>article</type><title>Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Roy, Sumon ; Kloner, Robert A. ; Salloum, Fadi N. ; Jovin, Ion S.</creator><creatorcontrib>Roy, Sumon ; Kloner, Robert A. ; Salloum, Fadi N. ; Jovin, Ion S.</creatorcontrib><description>The coexistence of cardiovascular disease and erectile dysfunction is widespread, possibly owing to underlying endothelial dysfunction in both diseases. Millions of patients with cardiovascular disease are prescribed phosphodiesterase-5 (PDE5) inhibitors for the management of erectile dysfunction. Although the role of PDE5 inhibitors in erectile dysfunction therapy is well established, their effects on the cardiovascular system are unclear. Preclinical studies investigating the effect of PDE5 inhibitors on ischemia–reperfusion injury, pressure overload-induced hypertrophy, and chemotoxicity suggested a possible clinical role for each of these medications; however, attempts to translate these findings to the bedside have resulted in mixed outcomes. In this review, we explore the biologic preclinical effects of PDE5 inhibitors in mediating cardioprotection. We then examine clinical trials investigating PDE5 inhibition in patients with heart failure, coronary artery disease, and ventricular arrhythmias and discuss why the studies likely have yet to show positive results and efficacy with PDE5 inhibition despite no safety concerns.</description><identifier>ISSN: 0920-3206</identifier><identifier>ISSN: 1573-7241</identifier><identifier>EISSN: 1573-7241</identifier><identifier>DOI: 10.1007/s10557-021-07275-y</identifier><identifier>PMID: 34652581</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Biological effects ; Cardiology ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - drug therapy ; Cardiovascular system ; Clinical trials ; Coexistence ; Congestive heart failure ; Coronary artery disease ; Cyclic Nucleotide Phosphodiesterases, Type 5 - therapeutic use ; Effectiveness ; Erectile dysfunction ; Erectile Dysfunction - drug therapy ; Heart ; Heart diseases ; Humans ; Hypertrophy ; Inhibitors ; Ischemia ; Male ; Medicine ; Medicine & Public Health ; Phosphodiesterase ; Phosphodiesterase 5 Inhibitors - adverse effects ; Reperfusion ; Review Article ; Safety ; Ventricle</subject><ispartof>Cardiovascular drugs and therapy, 2023-08, Vol.37 (4), p.793-806</ispartof><rights>Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c430t-7ba169f0cdeddf9c86832ca3c13cca64e90cdfadde91a6bfa0366ab7d5c87513</citedby><cites>FETCH-LOGICAL-c430t-7ba169f0cdeddf9c86832ca3c13cca64e90cdfadde91a6bfa0366ab7d5c87513</cites><orcidid>0000-0002-6258-0544 ; 0000-0002-4187-2919 ; 0000-0002-8947-9315 ; 0000-0003-4591-3252</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10557-021-07275-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10557-021-07275-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34652581$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roy, Sumon</creatorcontrib><creatorcontrib>Kloner, Robert A.</creatorcontrib><creatorcontrib>Salloum, Fadi N.</creatorcontrib><creatorcontrib>Jovin, Ion S.</creatorcontrib><title>Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety</title><title>Cardiovascular drugs and therapy</title><addtitle>Cardiovasc Drugs Ther</addtitle><addtitle>Cardiovasc Drugs Ther</addtitle><description>The coexistence of cardiovascular disease and erectile dysfunction is widespread, possibly owing to underlying endothelial dysfunction in both diseases. Millions of patients with cardiovascular disease are prescribed phosphodiesterase-5 (PDE5) inhibitors for the management of erectile dysfunction. Although the role of PDE5 inhibitors in erectile dysfunction therapy is well established, their effects on the cardiovascular system are unclear. Preclinical studies investigating the effect of PDE5 inhibitors on ischemia–reperfusion injury, pressure overload-induced hypertrophy, and chemotoxicity suggested a possible clinical role for each of these medications; however, attempts to translate these findings to the bedside have resulted in mixed outcomes. In this review, we explore the biologic preclinical effects of PDE5 inhibitors in mediating cardioprotection. We then examine clinical trials investigating PDE5 inhibition in patients with heart failure, coronary artery disease, and ventricular arrhythmias and discuss why the studies likely have yet to show positive results and efficacy with PDE5 inhibition despite no safety concerns.</description><subject>Biological effects</subject><subject>Cardiology</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - drug therapy</subject><subject>Cardiovascular system</subject><subject>Clinical trials</subject><subject>Coexistence</subject><subject>Congestive heart failure</subject><subject>Coronary artery disease</subject><subject>Cyclic Nucleotide Phosphodiesterases, Type 5 - therapeutic use</subject><subject>Effectiveness</subject><subject>Erectile dysfunction</subject><subject>Erectile Dysfunction - drug therapy</subject><subject>Heart</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Hypertrophy</subject><subject>Inhibitors</subject><subject>Ischemia</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Phosphodiesterase</subject><subject>Phosphodiesterase 5 Inhibitors - adverse effects</subject><subject>Reperfusion</subject><subject>Review Article</subject><subject>Safety</subject><subject>Ventricle</subject><issn>0920-3206</issn><issn>1573-7241</issn><issn>1573-7241</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kUtvFDEQhC0EIkvgD3BAI3HhYmjb47HNAQmtEogUCSRyt3r8yDraHS_2LNL8e5xsCI8DJx_qq2p3FyEvGbxlAOpdZSClosAZBcWVpMsjsmJSCap4zx6TFRgOVHAYTsizWm-gmYzRT8mJ6AfJpWYrcr7G4hO67izG4Oba5dh93eS632SfQp1DwRqo7C6mTRrTnEt9f4smh27pcPLdN4xhXp6TJxG3Nby4f0_J1fnZ1fozvfzy6WL98ZK6XsBM1YhsMBGcD95H4_SgBXcoHBPO4dAH06SI3gfDcBgjghgGHJWXTivJxCn5cIzdH8Zd8C5Mc8Gt3Ze0w7LYjMn-rUxpY6_zD2uAQa9MC3hzH1Dy90Pbz-5SdWG7xSnkQ7XtKFyD0nezXv-D3uRDmdp2luu-b6cFoxvFj5QrudYS4sNnGNjbluyxJdtasnct2aWZXv25xoPlVy0NEEegNmm6DuX37P_E_gTaSZ8p</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Roy, Sumon</creator><creator>Kloner, Robert A.</creator><creator>Salloum, Fadi N.</creator><creator>Jovin, Ion S.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6258-0544</orcidid><orcidid>https://orcid.org/0000-0002-4187-2919</orcidid><orcidid>https://orcid.org/0000-0002-8947-9315</orcidid><orcidid>https://orcid.org/0000-0003-4591-3252</orcidid></search><sort><creationdate>20230801</creationdate><title>Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety</title><author>Roy, Sumon ; Kloner, Robert A. ; Salloum, Fadi N. ; Jovin, Ion S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c430t-7ba169f0cdeddf9c86832ca3c13cca64e90cdfadde91a6bfa0366ab7d5c87513</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biological effects</topic><topic>Cardiology</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - drug therapy</topic><topic>Cardiovascular system</topic><topic>Clinical trials</topic><topic>Coexistence</topic><topic>Congestive heart failure</topic><topic>Coronary artery disease</topic><topic>Cyclic Nucleotide Phosphodiesterases, Type 5 - therapeutic use</topic><topic>Effectiveness</topic><topic>Erectile dysfunction</topic><topic>Erectile Dysfunction - drug therapy</topic><topic>Heart</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Hypertrophy</topic><topic>Inhibitors</topic><topic>Ischemia</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Phosphodiesterase</topic><topic>Phosphodiesterase 5 Inhibitors - adverse effects</topic><topic>Reperfusion</topic><topic>Review Article</topic><topic>Safety</topic><topic>Ventricle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roy, Sumon</creatorcontrib><creatorcontrib>Kloner, Robert A.</creatorcontrib><creatorcontrib>Salloum, Fadi N.</creatorcontrib><creatorcontrib>Jovin, Ion S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cardiovascular drugs and therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roy, Sumon</au><au>Kloner, Robert A.</au><au>Salloum, Fadi N.</au><au>Jovin, Ion S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety</atitle><jtitle>Cardiovascular drugs and therapy</jtitle><stitle>Cardiovasc Drugs Ther</stitle><addtitle>Cardiovasc Drugs Ther</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>37</volume><issue>4</issue><spage>793</spage><epage>806</epage><pages>793-806</pages><issn>0920-3206</issn><issn>1573-7241</issn><eissn>1573-7241</eissn><abstract>The coexistence of cardiovascular disease and erectile dysfunction is widespread, possibly owing to underlying endothelial dysfunction in both diseases. Millions of patients with cardiovascular disease are prescribed phosphodiesterase-5 (PDE5) inhibitors for the management of erectile dysfunction. Although the role of PDE5 inhibitors in erectile dysfunction therapy is well established, their effects on the cardiovascular system are unclear. Preclinical studies investigating the effect of PDE5 inhibitors on ischemia–reperfusion injury, pressure overload-induced hypertrophy, and chemotoxicity suggested a possible clinical role for each of these medications; however, attempts to translate these findings to the bedside have resulted in mixed outcomes. In this review, we explore the biologic preclinical effects of PDE5 inhibitors in mediating cardioprotection. We then examine clinical trials investigating PDE5 inhibition in patients with heart failure, coronary artery disease, and ventricular arrhythmias and discuss why the studies likely have yet to show positive results and efficacy with PDE5 inhibition despite no safety concerns.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34652581</pmid><doi>10.1007/s10557-021-07275-y</doi><tpages>14</tpages><orcidid>https://orcid.org/0000-0002-6258-0544</orcidid><orcidid>https://orcid.org/0000-0002-4187-2919</orcidid><orcidid>https://orcid.org/0000-0002-8947-9315</orcidid><orcidid>https://orcid.org/0000-0003-4591-3252</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0920-3206 |
| ispartof | Cardiovascular drugs and therapy, 2023-08, Vol.37 (4), p.793-806 |
| issn | 0920-3206 1573-7241 1573-7241 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9010479 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Biological effects Cardiology Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - drug therapy Cardiovascular system Clinical trials Coexistence Congestive heart failure Coronary artery disease Cyclic Nucleotide Phosphodiesterases, Type 5 - therapeutic use Effectiveness Erectile dysfunction Erectile Dysfunction - drug therapy Heart Heart diseases Humans Hypertrophy Inhibitors Ischemia Male Medicine Medicine & Public Health Phosphodiesterase Phosphodiesterase 5 Inhibitors - adverse effects Reperfusion Review Article Safety Ventricle |
| title | Cardiac Effects of Phosphodiesterase-5 Inhibitors: Efficacy and Safety |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T15%3A29%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiac%20Effects%20of%20Phosphodiesterase-5%20Inhibitors:%20Efficacy%20and%20Safety&rft.jtitle=Cardiovascular%20drugs%20and%20therapy&rft.au=Roy,%20Sumon&rft.date=2023-08-01&rft.volume=37&rft.issue=4&rft.spage=793&rft.epage=806&rft.pages=793-806&rft.issn=0920-3206&rft.eissn=1573-7241&rft_id=info:doi/10.1007/s10557-021-07275-y&rft_dat=%3Cproquest_pubme%3E2582807851%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2844920098&rft_id=info:pmid/34652581&rfr_iscdi=true |